Literature DB >> 9442787

Treatment of retinoblastoma vitreous base seeding.

S A Madreperla1, J L Hungerford, D Doughty, P N Plowman, J E Kingston, A D Singh.   

Abstract

OBJECTIVE: The purpose of the study is to describe results of a new treatment for retinoblastoma vitreous base seeding.
DESIGN: The study design was a retrospective review of patients treated at an ocular oncology referral center. PARTICIPANTS: Five eyes of five patients with vitreous base seeding that occurred after previous external beam radiation therapy were treated between October 1987 and December 1994. INTERVENTION: A customized plaque made from iridium-192/platinum wire was placed to deliver 4000 cGy to the tumor apex along its entire length and systemic chemotherapy (consisting of carboplatin, vincristine, and etoposide) was given. MAIN OUTCOME MEASURES: Eye preservation and tumor control were measured.
RESULTS: Vitreous base seeding was controlled completely and the eye preserved in four of the five treated eyes with an average follow-up of 26.2 months.
CONCLUSIONS: The combination of a customized iridium-192 plaque and systemic chemotherapy is an effective means of treating vitreous base seeding of retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442787     DOI: 10.1016/s0161-6420(98)91617-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?

Authors:  D S Gombos; P A Cauchi; J L Hungerford; P Addison; P G Coen; J E Kingston
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

2.  Globe conserving treatment of the only eye in bilateral retinoblastoma.

Authors:  V Lee; J L Hungerford; C Bunce; F Ahmed; J E Kingston; P N Plowman
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

3.  Palladium-103 plaque brachytherapy for retinoblastoma: Long term follow up.

Authors:  Abhilasha Maheshwari; Paul T Finger
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.